121 related articles for article (PubMed ID: 32436954)
1. Mechanistically derived patient-level framework for precision medicine identifies a personalized immune prognostic signature in high-grade serous ovarian cancer.
Zhao H; Gu S; Bao S; Yan C; Zhang Z; Hou P; Zhou M; Sun J
Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32436954
[TBL] [Abstract][Full Text] [Related]
2. Deep learning provides a new computed tomography-based prognostic biomarker for recurrence prediction in high-grade serous ovarian cancer.
Wang S; Liu Z; Rong Y; Zhou B; Bai Y; Wei W; Wei W; Wang M; Guo Y; Tian J
Radiother Oncol; 2019 Mar; 132():171-177. PubMed ID: 30392780
[TBL] [Abstract][Full Text] [Related]
3. Integrative analysis from multi-centre studies identifies a function-derived personalized multi-gene signature of outcome in colorectal cancer.
Sun J; Zhao H; Lin S; Bao S; Zhang Y; Su J; Zhou M
J Cell Mol Med; 2019 Aug; 23(8):5270-5281. PubMed ID: 31140730
[TBL] [Abstract][Full Text] [Related]
4. Predicting Response to Standard First-line Treatment in High-grade Serous Ovarian Carcinoma by Angiogenesis-related Genes.
Mendiola M; Redondo A; Heredia-Soto V; Herranz J; Berjón A; Hernández A; Miguel-Martín M; Crespo R; Barriuso J; Cruz P; Yébenes L; Peláez-García A; Castelo B; DE Molina AR; Feliu J; Hardisson D
Anticancer Res; 2018 Sep; 38(9):5393-5400. PubMed ID: 30194194
[TBL] [Abstract][Full Text] [Related]
5. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M
Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408
[TBL] [Abstract][Full Text] [Related]
6. Platform-Independent Classification System to Predict Molecular Subtypes of High-Grade Serous Ovarian Carcinoma.
Shilpi A; Kandpal M; Ji Y; Seagle BL; Shahabi S; Davuluri RV
JCO Clin Cancer Inform; 2019 Apr; 3():1-9. PubMed ID: 31002564
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of an immune gene-set based Prognostic signature in ovarian cancer.
Shen S; Wang G; Zhang R; Zhao Y; Yu H; Wei Y; Chen F
EBioMedicine; 2019 Feb; 40():318-326. PubMed ID: 30594555
[TBL] [Abstract][Full Text] [Related]
8. Immune profiling reveals prognostic genes in high-grade serous ovarian cancer.
Wu Y; Xia L; Zhao P; Deng Y; Guo Q; Zhu J; Chen X; Ju X; Wu X
Aging (Albany NY); 2020 Jun; 12(12):11398-11415. PubMed ID: 32544083
[TBL] [Abstract][Full Text] [Related]
9. Cox-LASSO Analysis Reveals a Ten-lncRNA Signature to Predict Outcomes in Patients with High-Grade Serous Ovarian Cancer.
Xu L; Wu Y; Che X; Zhao J; Wang F; Wang P; Qu X; Liu Y; Li Z
DNA Cell Biol; 2019 Dec; 38(12):1519-1528. PubMed ID: 31657627
[TBL] [Abstract][Full Text] [Related]
10. Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer.
Pinto MP; Balmaceda C; Bravo ML; Kato S; Villarroel A; Owen GI; Roa JC; Cuello MA; Ibañez C
Gynecol Oncol; 2018 Oct; 151(1):10-17. PubMed ID: 30078505
[TBL] [Abstract][Full Text] [Related]
11. Integrative proteogenomic analyses of human tumours identifies ADNP as a novel oncogenic mediator of cell cycle progression in high-grade serous ovarian cancer with poor prognosis.
Karagoz K; Mehta GA; Khella CA; Khanna P; Gatza ML
EBioMedicine; 2019 Dec; 50():191-202. PubMed ID: 31767542
[TBL] [Abstract][Full Text] [Related]
12. A 2-Protein Signature Predicting Clinical Outcome in High-Grade Serous Ovarian Cancer.
Jin C; Xue Y; Li Y; Bu H; Yu H; Zhang T; Zhang Z; Yan S; Lu N; Kong B
Int J Gynecol Cancer; 2018 Jan; 28(1):51-58. PubMed ID: 28976449
[TBL] [Abstract][Full Text] [Related]
13. Development of a multi-gene-based immune prognostic signature in ovarian Cancer.
Cao T; Shen H
J Ovarian Res; 2021 Jan; 14(1):20. PubMed ID: 33509250
[TBL] [Abstract][Full Text] [Related]
14. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
Miller KR; Patel JN; Zhang Q; Norris EJ; Symanowski J; Michener C; Sehouli J; Braicu I; Destephanis DD; Sutker AP; Jones W; Livasy CA; Biscotti C; Ganapathi RN; Tait DL; Ganapathi MK
Gynecol Oncol; 2018 Apr; 149(1):155-162. PubMed ID: 29402501
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma.
Qu L; Wang ZL; Chen Q; Li YM; He HW; Hsieh JJ; Xue S; Wu ZJ; Liu B; Tang H; Xu XF; Xu F; Wang J; Bao Y; Wang AB; Wang D; Yi XM; Zhou ZK; Shi CJ; Zhong K; Sheng ZC; Zhou YL; Jiang J; Chu XY; He J; Ge JP; Zhang ZY; Zhou WQ; Chen C; Yang JH; Sun YH; Wang LH
Eur Urol; 2018 Dec; 74(6):756-763. PubMed ID: 30143382
[TBL] [Abstract][Full Text] [Related]
16. Genomic Rearrangement Signatures and Clinical Outcomes in High-Grade Serous Ovarian Cancer.
Hillman RT; Chisholm GB; Lu KH; Futreal PA
J Natl Cancer Inst; 2018 Mar; 110(3):265-72. PubMed ID: 29584920
[TBL] [Abstract][Full Text] [Related]
17. Proteases and their inhibitors as prognostic factors for high-grade serous ovarian cancer.
Trudel D; Avarvarei LM; Orain M; Turcotte S; Plante M; Grégoire J; Kappelhoff R; Labbé DP; Bachvarov D; Têtu B; Overall CM; Bairati I
Pathol Res Pract; 2019 Jun; 215(6):152369. PubMed ID: 30987833
[TBL] [Abstract][Full Text] [Related]
18. Serum CD95L Level Correlates with Tumor Immune Infiltration and Is a Positive Prognostic Marker for Advanced High-Grade Serous Ovarian Cancer.
De La Motte Rouge T; Corné J; Cauchois A; Le Boulch M; Poupon C; Henno S; Rioux-Leclercq N; Le Pabic E; Laviolle B; Catros V; Levêque J; Fautrel A; Le Gallo M; Legembre P; Lavoué V
Mol Cancer Res; 2019 Dec; 17(12):2537-2548. PubMed ID: 31537619
[TBL] [Abstract][Full Text] [Related]
19. Development and Validation of an Immune-Related Gene-Pair Model of High-Grade Serous Ovarian Cancer After Platinum-Based Chemotherapy.
Lin J; Xu X; Sun D; Li T
Front Oncol; 2020; 10():626555. PubMed ID: 33680950
[TBL] [Abstract][Full Text] [Related]
20. A BRCA1/2 Mutational Signature and Survival in Ovarian High-Grade Serous Carcinoma.
Dong F; Davineni PK; Howitt BE; Beck AH
Cancer Epidemiol Biomarkers Prev; 2016 Nov; 25(11):1511-1516. PubMed ID: 27496093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
